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Background
In Denmark, Omalizumab is approved for treating
children with severe persistent allergic asthma older than
6 years of age. No systematic registration of the efficacy in
the Danish child population according to asthma symp-
toms or the efficacy on co-morbid allergic symptoms
exists. A broad panel of outcome measures is necessary to
evaluate the efficacy of Omalizumab treatment.
Aim
To provide a standardized systematic registration in
order to create a database enrolling children with severe
allergic asthma treated with Omalizumab.
Method and study design
A national multicenter registration and follow-up study
based on children with clinical persistent severe allergic
asthma including both retrospective and prospective
registration.
Inclusion criteria
Children, 6-18 years of age, with severe persistent allergic
asthma according to GINA treated with Omalizumab.
Outcome registration
A broad panel of outcome measures is scheduled at











• Quality of life score. (Juniper)
• Rhinitis score, R-RTSS
• SCORAD score
The monitoring plan and follow-up programme will
be presented in a flowchart.
Conclusion
We believe that a national systematic registration will
increase knowledge regarding efficacy of Omalizumab
treatment in this rare group of severe allergic asthmatic
children.
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